NASDAQ$OLMA
Olema Pharmaceuticals Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Olema Oncology reported financial results for Q1 2023 and provided a corporate update.
Olema Oncology reported a net loss of $28.3 million for the first quarter of 2023. As of March 31, 2023, cash, cash equivalents and marketable securities totaled $186.0 million, expected to fund operations into 2025.
- First pivotal Phase 3 monotherapy clinical trial of OP-1250 planned for the second half of 2023.
- Interim Phase 2 clinical results of OP-1250 in combination with palbociclib to be presented at the 2023 ESMO Breast Cancer Annual Congress on May 12, 2023.
- Phase 2 monotherapy and initial ribociclib combination clinical results expected to be presented in the second half of 2023.
- Cash, cash equivalents and marketable securities of $186.0 million as of March 31, 2023.
Headline financials
Revenue & EPS history
Olema · Revenue · Quarterly
$0
Forward guidance
Olema anticipates that its cash balance will be sufficient to fund operations into 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
-0.1%
Avg return
Earnings day
-2.4%
Avg return
5 days after
+7.5%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+17.0%
Q4 2021
Best reaction
-28.5%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.2% | -7.7% | -29.4% | |
| Q3 2025 | +4.1% | +0.6% | +267.4% | |
| Q2 2025 | +16.0% | +20.6% | +75.1% | |
| Q1 2025 | +2.1% | +9.6% | -11.0% | |
| Q4 2024 | -8.5% | +4.3% | +6.8% | |
| Q3 2024 | -9.7% | -27.9% | -47.2% | |
| Q1 2024 | -12.5% | -18.0% | +16.8% | |
| Q4 2023 | -6.6% | -11.2% | -15.8% | |
| Q3 2023 | -7.6% | -7.4% | -29.2% | |
| Q2 2023 | +15.3% | +14.0% | +24.7% | |
| Q1 2023 | +1.1% | +6.1% | -0.3% | |
| Q4 2022 | +0.0% | +0.3% | -15.4% | |
| Q3 2022 | -7.2% | +5.6% | -22.5% | |
| Q2 2022 | -28.5% | -29.4% | -23.1% | |
| Q1 2022 | -1.3% | -3.1% | +79.4% | |
| Q4 2019 | +17.0% | -2.2% | -5.9% | |
| Q4 2021 | +17.0% | -2.2% | -5.9% | |
| Q3 2021 | +1.1% | -1.9% | -61.9% | |
| Q3 2020 | +1.1% | -1.9% | -61.9% | |
| Q2 2020 | +3.4% | +1.9% | +11.2% | |
| Q2 2021 | +3.4% | +1.9% | +11.2% | |
| Q1 2021 | +11.9% | +14.8% | +35.8% | |
| Q4 2020 | -10.2% | -23.2% | -27.2% | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro